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introduction: Rituximab (RTX) is a monoclonal antibody targeting CD20, a transmem-
brane protein expressed on B  cells, causing B  cell depletion. RTX has shown great 
efficacy in studies of pemphigus vulgaris, but data of pemphigoid diseases are limited.
Objective: To assess the effectiveness and safety of RTX in pemphigoid diseases.
Methods: The medical records of 28 patients with pemphigoid diseases that were treated 
with RTX were reviewed retrospectively. Early and late endpoints, defined according 
to international consensus, were disease control (DC), partial remission (PR), complete 
remission (CR), and relapses. Safety was measured by reported adverse events.
results: Patients with bullous pemphigoid (n =  8), mucous membrane pemphigoid 
(n = 14), epidermolysis bullosa acquisita (n = 5), and linear IgA disease (n = 1) were 
included. Treatment with 500 mg RTX (n = 6) or 1,000 mg RTX (n = 22) was administered 
on days 1 and 15. Eight patients received additional 500 mg RTX at months 6 and 12. 
Overall, DC was achieved in 67.9%, PR in 57.1%, and CR in 21.4% of the cases. During 
follow-up, 66.7% patients relapsed. Repeated treatment with RTX led to remission (PR 
or CR) in 85.7% of the retreated cases. No significant difference in response between 
pemphigoid subtypes was found. IgA-dominant cases (n =  5) achieved less DC (20 
vs. 81.3%; p = 0.007), less PR (20 vs. 62.5%; p = 0.149), and less CR (0 vs. 18.8%; 
p = 0.549) compared to IgG-dominant cases (n = 16). Five severe adverse events and 
three deaths were reported. One death was possibly related to RTX and one death was 
disease related.
conclusion: RTX can be effective in recalcitrant IgG-dominant pemphigoid diseases, 
however not in those where IgA is dominant.
Keywords: pemphigoid diseases, autoimmune bullous diseases, rituximab, iga, mucous membrane pemphigoid, 
linear iga disease, epidermolysis bullosa acquisita, case series
Abbreviations: RTX, rituximab; BMZ, basement membrane zone; BP, bullous pemphigoid; MMP, mucous membrane pemphi-
goid; EBA, epidermolysis bullosa acquisita; LAD, linear IgA disease; RA, rheumatoid arthritis; DIF, direct immunofluorescence 
microscopy; IIF, indirect immunofluorescence microscopy; SSS, salt-split skin; DC, disease control; PR, partial remission; CR, 
complete remission; HIVIg, human intravenous immunoglobulin; MTX, methotrexate; AZA, azathioprine; cyclo, cyclophos-
phamide; MMF, mycophenolate mofetil; IV, intravenous.
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inTrODUcTiOn
Pemphigoid diseases are a heterogeneous group of autoantibody-
mediated subepidermal blistering diseases (1). IgG, IgA, or IgM 
autoantibodies target distinct antigens located in the basement 
membrane zone (BMZ) inducing different pemphigoid subtypes. 
Cutaneous pemphigoid is the subgroup of pemphigoid diseases 
that predominantly affect the skin (1, 2). Pemphigoid, be it non-
bullous or bullous (BP), is the most prevalent disease within this 
subgroup and mainly presents at older age (3). Mucous membrane 
pemphigoid (MMP) opposes cutaneous pemphigoid in the spec-
trum of pemphigoid diseases, and is characterized by primary 
involvement of the mucosa (2, 4). Beside the classification based 
on body localization, pemphigoid diseases may be classified 
based on targeted auto-antigens, such as 180  kDa BP antigen 
(BP180) and the 230  kDa BP antigen (BP230) in pemphigoid, 
laminin-332 in anti-laminin-332 MMP, the p200 protein in anti-
p200 pemphigoid (anti-laminin γ1 pemphigoid), and type VII 
collagen in epidermolysis bullosa acquisita (EBA) (2). Last, classi-
fication may be based on predominant class of autoantibodies IgG 
or IgA. Pemphigoid diseases with the exclusive IgA involvement 
are named linear IgA disease (LAD), regardless of the targeted 
antigen or clinical presentation (5). IgA-mediated pemphigoid 
diseases are difficult to treat if dapsone is contraindicated, and 
mostly show high resistance to usual immunosuppressants (6).
The 2014 European consensus guideline for the management 
of BP recommends transcutaneous systemic clobetasol therapy as 
initial treatment (7, 8). The alternative is oral systemic prednisolone 
therapy (0.5–1.0 mg/kg/day), which was associated with adverse 
events and higher mortality (8, 9). Recently, doxycycline was found 
to be non-inferior to and safer than prednisolone for short-term 
blister control (10), although the statistical margins were wide (11). 
As third-line rituximab (RTX) is recommended in cases in which 
conventional immunosuppressive drugs were not effective, were 
contraindicated, or showed unacceptable side effects (8, 12, 13).
Rituximab is a chimeric monoclonal antibody targeting CD20, 
a transmembrane protein expressed by all B cells in the pre-plasma 
cell lineage (14). Binding of RTX to CD20 leads to B cell depletion 
in the peripheral circulation by various mechanisms (15). RTX is 
registered for treatment of B cell lymphoma’s, rheumatoid arthri-
tis (RA), and granulomatosis with polyangiitis (15, 16). Recently, 
RTX was shown to be effective as first-line therapy in pemphigus 
(17). However, the position of RTX on the therapeutically ladder 
of pemphigoid diseases is unknown. Data regarding the effective-
ness and safety of RTX in pemphigoid diseases are limited and are 
mainly of retrospective nature (18–26). Furthermore, it is unclear 
which treatment regime is most beneficial and which factors 
might be predictive for treatment response (27, 28). Therefore, 
the aim of our study was to retrospectively analyze our daily prac-
tice experience with RTX in pemphigoid diseases by evaluating 
the effectiveness and safety, and to identify clinical or serological 
factors that might be associated with treatment response.
MaTerials anD MeThODs
All patients with pemphigoid diseases treated with RTX between 
2010 and September 2017 at the Center for Blistering Diseases 
at the University Medical Center Groningen were included in 
the study. Pemphigoid diseases were diagnosed based on the fol-
lowing criteria: linear depositions of IgG, IgA, IgM, or C3c along 
the BMZ by direct immunofluorescence microscopy (DIF) and/
or positive indirect immunofluorescence microscopy (IIF) on 
monkey esophagus (MO) or salt-split skin (SSS), in combination 
with clinical presentation, histopathological findings, or other 
immunoserological tests compatible with the diagnosis of a pem-
phigoid disease. Patients with a linear u-serrated immunodeposi-
tion pattern seen by DIF were diagnosed with EBA. Patients with 
exclusive involvement of IgA were diagnosed with LAD.
Patients charts were reviewed retrospectively by the first 
(Aniek Lamberts) and second (H. Ilona Euverman) authors. 
Response outcomes were defined according to international con-
sensus and measured by the early endpoint disease control (DC), 
and the late endpoints partial remission (PR), complete remission 
(CR), and the number of relapses (29, 30). Safety was measured 
by reported adverse events. Discrepancies in the assessment by 
Aniek Lamberts and H. Ilona Euverman were resolved through 
discussion with the other authors (Barbara Horváth and Marcel 
F. Jonkman).
Treatment regimes
There were two treatment protocols administered. In the period 
of 2010–2012, patients were treated with RTX 500  mg at days 
1 and 15 (low-dose RA protocol), since this dose was effective 
in pemphigus patients (Horvath et al. 2011) (31, 32). Additional 
500  mg RTX at month 6 and/or 12 was only administered on 
indication (33). From 2012 the protocol was adjusted to 1,000 mg 
RTX at days 1 and 15 (high-dose RA protocol—published in 
2011) (28). Since 2014, patients standardly received additional 
500 mg RTX at months 6 and 12, and if indicated at month 18. 
Patients that relapsed within 1 year after the last RTX infusion 
received re-treatment with a single infusion of 500  mg RTX. 
Relapsed patients beyond 1 year after the last RTX infusion were 
retreated with a new cycle of 1,000 mg RTX at days 1 and 15.
statistical analysis
The Kolmogorov–Smirnov test was used to test for normal distri-
butions. Correlations between bivariate outcome measures were 
analyzed with Fisher’s exact test. Comparing means of non-nor-
mally distributed data was done with the Mann–Whitney U test. 
Statistical significance was defined by a p-value <0.05. Statistical 
analyses were performed in IBM SPSS statistics version 23.
resUlTs
Patient Population
A total of 28 patients were included. The patient characteristics 
are listed in Table 1. The mean delay in diagnosis was 10.5 months 
in BP (range 1–19), 24.3  months in MMP (range 4–60), and 
19.0  months in EBA patients (range 3–47). One MMP outlier 
with an exceptional long delay in diagnosis of 285 months was 
not taken into account. This patient showed severe laryngeal, 
oral, genital, and ocular (foster stage 4) involvement. The mean 
time between diagnosis and RTX treatment was longer for BP 
Table 1 | Demographics of pemphigoid patients treated with RTX.
Mean age at first cycle RTX BP (n = 8)a 67.13 years SD 9.4, range 53–78





EBA, all inflammatory subtype (n = 5) 54.0 years SD 22.8, range 25–87
LAD (n = 1) 48.0 years –
Total (n = 28) 63.0 years SD 14.3, range 25–87
Dominant Ig in DIF and IIF on SSS IgG dominant 16 patients
IgA dominant 5 patients
IgM dominant 1 patient
IgG/IgA equally dominant 6 patients
Gender Male 13 (46.4%)
Female 15 (53.6%)
First cycle of 2 × 500 mg 6 patients
Additional cycle 2 × 1,000 mg 3 patients
Additional cycle 2 × 500 mg 1 patient
First cycle of 2 × 1,000 mg 22 patientsc
Additional cycle 2 × 1,000 mg 1 patients
Additional cycle 2 × 500 mg 1 patient
Additional gifts of RTX 500 mg at M6 and/or M12 15 patientsd
500 mg at M6 and M12 8 patients
Mean total follow-up time (first RTX cycle till last contact) 30.3 months SD 23.0, range 2–79
RTX, rituximab; BP, bullous pemphigoid; MMP, mucous membrane pemphigoid; EBA, epidermolysis bullosa acquisita; LAD, linear IgA disease; Ig, immunoglobulin; DIF, direct 
immunofluorescence microscopy; IIF, indirect immunofluorescence microscopy; SSS, salt-split skin; M6, month 6; M12, month 12.
aAll patients with pemphigoid presented with the BP.
bTwo patients had exclusive ocular involvement, also known as pure ocular MMP.
cOne patient only received 1 × 1,000 mg due to the development of pneumocystis pneumonia.
dFive patients only received 500 mg RTX at M6, two patients only received 500 mg RTX at M12.
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patients (64.3 months; range 1–272), EBA (29.1 months; range 
0.5–84), and LAD patients (49.0  months) compared to MMP 
(13.8  months; range 2–63). Prior to RTX, all patients received 
one or more immunosuppressants (Table S1 in Supplementary 
Material) with suboptimal effect or with unacceptable side effects. 
Therefore, RTX was administered as last resort in several cases. 
Six patients received low-dose RTX (500  mg) and 22 patients 
high-dose RTX (1,000 mg), of which eight patients also received 
repeated RTX doses (500 mg) at months 6 and 12. In all patients 
RTX was added to pre-existing treatment with a local steroid 
and/or one or two systemic drugs (Table S1 in Supplementary 
Material).
effectiveness of First course of rTX
DC was achieved in 19 of 28 patients (67.9%) at a mean time of 
14.5 weeks (range 1–36; SD 9.1). Remission (partial or complete) 
was achieved by 57.1% (n = 16) of the treatment resistant pem-
phigoid cases (Figures 1 and 2). PR was achieved by 16 patients 
(57.1%) at a mean time of 34.2 weeks (range 9–71; SD 18.1). Six of 
28 patients (21.4%) also achieved CR at a mean time of 59.2 weeks 
(range 24–85; SD 22.1). Figures 3 and 4 display a flowchart and bar 
chart of the achieved early and late endpoints during follow-up. A 
complete overview of the outcome measurements of all included 
patients can be found in Table S1 in Supplementary Material.
We analyzed whether early administration of RTX was 
more beneficial. We compared the mean time between onset 
of symptoms and RTX treatment of patients with PR or CR 
(52.2 months; n = 16) and patients without PR or CR (64.9 months; 
n = 12). No significant difference was found [Mann–Whitney test 
(p = 0.642)].
comparison of Treatment regimes
Significantly more patients achieved DC with 1,000  mg RTX 
at days 1 and 15 (85.0%) compared to 500  mg RTX (33.3%; 
p = 0.028). Furthermore, patients more often achieved PR (63.6 
vs. 16.7%; p = 0.057) and CR (27.3 vs. 0%; p = 0.289). Relapses 
were seen in both two cases receiving 500 mg RTX and 12 out of 
19 cases (63.2%) with 1,000 mg RTX (p = 0.533).
Patients receiving repeated RTX infusions (n = 8) achieved DC 
(100 vs. 63.2%; p = 0.134) and PR (87.5 vs. 45.0%; p = 0.088) more 
frequently than patients without additional RTX infusions. A 
similar number of patients achieved CR (25.0 vs. 20%; p = 1.000). 
The relapse rate in the group with the additional gifts was lower 
(50.0 vs. 76.9%; p = 0.346), and the mean time until relapse was 
longer [81.3 weeks (range 32–170; SD 62.3) vs. 69.0 weeks (range 
12–238; SD 66.6); p = 0.572].
response in the Different Pemphigoid 
subtypes
Mucous membrane pemphigoid patients showed the most benefit 
of RTX with DC in 85.7%, PR in 64.3%, and CR in 28.6% patients. 
During follow-up, 75% of the MMP patients relapsed. BP patients 
FigUre 2 | Epidermolysis bullosa acquisita (EBA) in a 59-year-old female. 
(a) Nummular erythematous plaques, papules and circinate configurated 
crustae, vesicles, and bullae on the trunk, before rituximab (RTX) treatment. 
(b) Remission off therapy after RTX treatment.
FigUre 1 | Bullous pemphigoid in a 69-year-old male. (a,c) Erythematous 
plaques and papules on both legs before rituximab (RTX) treatment. (b,D) 
Remission with minimal therapy after RTX treatment.
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was found in the effectiveness of RTX between the different 
pemphigoid subtypes by Fisher’s exact test.
immunological Findings
The dominant immunoglobulin class prior to RTX treatment 
assessed by staining intensity in DIF and IIF on SSS was IgG in 
the majority of the cases (57.1%; n = 16), IgA in 17.9% (n = 5), 
and IgM in 3.6% (n = 1). Equal intensity of IgA and IgG stain-
ing was observed in 21.4% (n = 6) of the cases. IgA-dominant 
pemphigoid cases (n =  5) showed significantly less DC (20 vs. 
81.3%; p = 0.007) compared to IgG-dominant cases (n = 16). The 
proportion of patients achieving PR (20 vs. 62.5%; p = 0.149) and 
CR (0 vs. 18.8%; p = 0.549) did not differ significantly; however, it 
showed a clear trend of ineffectiveness of RTX in IgA-dominant 
cases. Post treatment analysis was not performed.
Deposition of C3c along the BMZ was seen in 67.9% (n = 19) 
of DIF biopsies. No differences in effectiveness of RTX were 
found between patients with or without complement depositions.
relapses
Fourteen of 21 patients (66.7%) relapsed after a mean time of 
72.5 weeks (range 12–238; SD 63.2). Four of 14 relapsed patients 
showed B cell repopulation; in one case repopulation preceded 
relapse and in three cases repopulation was objectified after the 
relapse. Five of 14 relapsed patients showed maintained B  cell 
depletion and in five patients B cells were not followed up. Seven 
of 14 relapsed patients were retreated with RTX, which led to PR 
or CR in six out of seven patients (85.7%).
safety
Table  2 provides an overview of reported adverse events and 
deaths after RTX treatment. One patient died 4  months after 
RTX infusion due to sepsis which led to multi-organ failure. 
This death was interpreted as possibly related to RTX, since 
neutropenia (possibly RTX induced late onset neutropenia) 
might have contributed to a higher infection risk. All cases that 
reported grade 3 or grade 4 adverse events fully recovered. Five 
infusion reactions were observed in three patients during RTX 
administration: dyspnea with chest pain, tired feeling of the legs, 
and dizziness plus a burning sensation in the groins. All infu-
sions could be successfully continued at lower infusion rate. One 
patient was accidently shortly infused with RTX subcutaneously, 
causing temporary pain and swelling of the arm.
b cell Depletion
B cells were undetectable in the peripheral blood within 2 weeks 
in all patients after a single RTX infusion. In 13 patients, B cell 
levels remained undetectable during a mean follow-up time of 
77.5  weeks (range 24–269; SD 64.6). All 13 patients received 
repeated RTX infusions at months 6, 12, or both. Repopulation 
of B cells was seen in six patients after a mean time of 95.2 weeks 
(range 36–250; sd 82.4). B cell levels were not followed up in nine 
patients. B cell levels showed no clear relation with response to 
RTX. All data on B cell levels should be interpreted with caution, 
since B cells were not measured at standard time points in our 
study population.
achieved DC in 83.3%, PR in 62.5%, and CR in 12.5% with a 
relapse rate of 71.4%. In EBA patients, DC was found in 40%, PR 
in 40%, and CR in 20% without relapse. The patient with LAD 
was unresponsive to RTX treatment. No significant difference 
FigUre 3 | Flowchart of the effectiveness of RTX in pemphigoid patients, showing the highest endpoint reached after the first RTX cycle. RTX, rituximab; DC, 
disease control; PR, partial remission; CR, complete remission. aTwo patients already achieved DC before RTX was administered.
FigUre 4 | Bar chart showing the achieved endpoints and repeated treatment of RTX of each individual pemphigoid patient. Bars represent patients until the end 
of follow-up. The pemphigoid subtypes are indicated on the y-axis and the x-axis displays time in years. RTX, rituximab; BP, bullous pemphigoid; MMP, mucous 
membrane pemphigoid; EBA, epidermolysis bullosa acquisita; LAD, linear IgA disease.
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Table 2 | Adverse events and deaths reported in pemphigoid patients treated with rituximab (RTX).
graDea concomitant immunosuppressive drugs
reported adverse events
Patient 1 Erysipelas right arm 3 Prednisolone 30 mg/day
Herpes simplex labialis (confirmed HSV-1) 2 Prednisolone 30 mg/day
Patient 2,3 Upper respiratory infection probably viral (not confirmed) 1 Patient 2: prednisolone 10 mg/day
Patient 3: none
Patient 4 PCP twice (no prophylaxis)
- after first gift of 1,000 mg RTX
4 Prednisolone 60 mg/day + cyclophosphamide 150 mg/day
- after second cycle of 2 × 1,000 mg RTX 4 Prednisolone 20 mg/day
Patient 5 Urticaria e.c.i., self-limiting 1 Prednisolone 15 mg/day
Patient 6 Flare-up of concomitant psoriasis 2 Prednisolone 10 mg/day + dapsone 100 mg/day
Patient 7 Polyarthritis and fever, possibly caused by serum sickness (not 
confirmed) 
3 Prednisolone 7.5 mg/day
Patient 8 Diarrhea and loss of consciousness, followed by hospitalization 3 Prednisolone 40 mg/day
Patient 9 Generalized pain e.c.i., self-limiting 2 Prednisolone 35 mg/day
Urinary tract infection (female) 2 Prednisolone 35 mg/day
Patient 10 Upper respiratory infection probably viral (not confirmed) 2 Prednisolone 5 mg/day + cyclophosphamide 50 mg/day
Urinary tract infection (male) 2 Prednisolone 5 mg/day + cyclophosphamide 50 mg/day
Patient 11 Myalgia e.c.i., self-limiting 1 Prednisolone 5 mg/day
Deaths that occurred after rTX administration
Male, 78 years old, BP Cognitive and physical decline. Exact cause of death unknown
Female, 73 years old, BP Sepsis due to neglected urinary tract infection and neutropenia/leukopenia 
(possibly late onset neutropenia due to RTX), multi-organ failure eventually 
led to death
Female, 87 years old, EBA Active disease with severe mucosal involvement, weight loss and physical 
decline, exact cause of death unknown (possibly disease related)
RTX, rituximab; HSV-1, Herpes Simplex Virus type 1; PCP, pneumocystis pneumonia; e.c.i., e causa ingnota (of unknown cause); BP, bullous pemphigoid; MMP, mucous membrane 
pemphigoid; EBA, epidermolysis bullosa acquisita; LAD, linear IgA disease.
aAdverse events were graded according to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) (34).
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DiscUssiOn
Our study showed partial or CR with RTX in 57.1% of the cases 
with a pemphigoid disease, that previously failed on a variety 
of immunosuppressants. RTX was most beneficial in refractory 
MMP and BP patients with partial or CR in 64.3 and 62.5% of 
the cases. Interestingly, IgA-dominant pemphigoid diseases 
responded poorly on RTX.
Only two other studies described RTX treatment of MMP 
patients (n =  14; 11 cases with isolated ocular involvement) 
according to the RA protocol and showed PR or CR in all 
cases (19, 20). Both studies reported high relapse rates (83.3 
and 100%); however, repeated treatment led to remission in 
all cases. These findings are in accordance with our observed 
relapse rate (66.7%) and remission rate after repeated RTX 
treatment (85.7%).
Previous studies on RTX therapy in MMP and BP reported 
either mixed responses with serious infectious adverse events 
and death (24–26), or high remission rates with limited non-
serious adverse events (18–23). Studies on RTX in combination 
with immunoadsorption (protein A) or human intravenous 
immunoglobulin found high response rates in ocular MMP, 
resistant EBA, and recalcitrant BP (35–38). Interestingly, our 
study showed lower remission rates compared to most reports 
in the literature; DC in 100% (21) , PR and/or CR in 66% (24), 
86% (25), 88% (26), 92% (18), and 100% (23) . These differences 
in the results can be explained by the clinical heterogeneity of the 
previous studies, caused by using different RTX regimes (21, 22, 
24–26), by assessing different populations (multiple pemphigoid 
subtypes in a tertiary referral center in our study, MMP patients 
in most studies) (19–21, 26, 36) , or by using different definitions 
for the outcome measurements (19, 22, 23, 39). Studies prior 
to the pemphigoid consensus of 2012 either used definitions of 
the pemphigus consensus of 2008, in which minimal adjuvant 
therapy was less well defined, or other definitions for treatment 
response (19, 22, 23, 39).
An important result is the observation of significantly more 
DC (p = 0.028), and more PR (p = 0.057) and CR (p = 0.289) in 
patients treated with a high dosage regime compared to a low dos-
age regime. Moreover, we noticed a beneficial effect of repeated 
RTX infusions with less relapses.
A major finding of our study is that four out of five (80%) IgA-
dominant pemphigoid diseases were completely unresponsive 
to RTX treatment. Previously, He et al. demonstrated persistent 
IgA-secreting plasma cells in a MMP patient not responding to 
RTX treatment (40). They speculated that plasma cells could be 
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derived from a tissue resident memory B cell population that is 
resistant to anti-CD20 therapy. Mei et al. described the continu-
ous presence of IgA + plasma cells in the peripheral circulation 
and the gastrointestinal mucosa of RA patients during successful 
B  cell depletion by RTX (41). Further characterization of the 
circulating plasma cells revealed a mucosal phenotype, indicating 
that their precursor B cells are mucosal resident, and not depleted 
by RTX. All these findings could explain the unresponsiveness in 
our IgA-dominant cases.
Fourteen adverse events were reported in 11 (39.3%) 
pemphigoid cases treated with RTX. The majority of adverse 
events were infectious (n = 8). Five adverse event were severe 
(grade 3 of 4), and one reported death was possibly related 
to RTX. Noteworthy is one disease-related death in an older 
EBA patient, demonstrating that pemphigoid diseases can be 
life-threatening in therapy resistant cases and underlining 
the urgent need for effective treatment options. Our safety 
data is comparable with the reports of Maley et  al. and Cho 
et  al. who found adverse events in 33 and 31% of the MMP 
patients treated with RTX (18, 21). Yet, both studies observed 
a significantly higher adverse event rate in patients treated 
with conventional therapies (48 and 53%). Other studies have 
reported less adverse events compared to our data (23, 35–37). 
This might be explained by the frequent use of concomitant 
immunosuppressive drugs in our population with high disease 
severity, causing a high risk of infection.
Pemphigoid diseases appear to respond less on RTX than 
pemphigus, despite successful B cell depletion in the peripheral 
circulation in both diseases (17, 32). Furthermore, our data 
also showed that it takes almost 4 months (mean time till DC is 
14.4 weeks) until RTX has effect, whereas in pemphigus effect is 
noticed within 2 months (DC at 4.0–9.3 weeks) (42–46). Possibly, 
B  cell depletion stops pathogenic autoantibody production in 
both diseases, though other ongoing pathophysiological mecha-
nisms that are not interrupted by B cell depletion might play a 
more substantial role in the pathogenesis of pemphigoid (27, 
47). Nevertheless, PR and CR in responding pemphigoid disease 
patients was reached after the same time or slightly later than in 
pemphigus patients (32, 45, 46).
The greatest limitation of this study is its retrospective nature, 
which led to incomplete and/or missing data, such as objective 
disease scores (BPDAI and MMPDAI), and laboratory measure-
ments of B cells and pathogenic autoantibodies at standard time 
points. Furthermore, a major limitation is the small sample size, 
especially when comparing the different pemphigoid subtypes, 
and the heterogeneity of our study population. The use of con-
comitant immunosuppressants in almost all patients (Table S1 
in Supplementary Material) did not allow us to draw conclusions 
regarding RTX monotherapy. Nonetheless, the immunosuppres-
sants alone did not succeed to establish DC or remission prior 
to RTX treatment. Moreover, the use of co-medication in severe 
pemphigoid diseases does reflect upon our daily practice. Lastly, 
it is important to emphasize that consensus late endpoints PR 
and CR imply to define two contrasting outcomes, but in clinical 
setting the difference can be minimal (one insignificant lesion 
once weekly vs. no lesions); therefore, patients on PR and CR 
might be equally satisfied with treatment result. Prospective stud-
ies with a greater sample size are needed to provide a higher level 
of evidence on the effectiveness of RTX in pemphigoid diseases.
In conclusion, this study demonstrated that RTX was effective 
in 57.1% of recalcitrant pemphigoid diseases and that the high 
dose regime of twice 1,000 mg was more effective than the low 
dose. Although relapse rates were high (66.7%), repeated RTX 
therapy led to remission in the majority of the relapsed cases 
(85.7%). An important finding is that most pemphigoid patients 
with IgA-dominant disease showed poor response to RTX. This 
finding suggests that RTX can be eliminated from the clinicians’ 
arsenal when encountering IgA-dominant pemphigoid patients; 
however, future studies are required for confirmation. RTX 
showed to be relatively safe. Prospective comparative studies are 
needed to further determine the position of RTX in the therapeu-
tic algorithm for pemphigoid diseases.
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